Apituitary tumor with suprasellar extension was found by magnetic resonance imaging (MRI) in a male with diabetes mellitus. Endocrine examination revealed high plasma folliclestimulating hormone (FSH) and a-subunit levels, which increased with administration of thyrotropin (TSH)-releasing hormone (TRH). Plasma luteinizing hormone (LH) and testosterone levels were low. Pituitary gonadotropin producing tumor was diagnosed. Because the patient refused surgery, bromocriptine was administered and plasma FSH and a-subunit rapidly decreased; on MRIthe tumor size was gradually reduced. Whenpituitary operation is not feasible, bromocriptine is one choice of treatment. (Internal Medicine 38: 266-271, 1999) 
Introduction
Gonadotroph cell adenoma (gonadotropinoma) was formerly rarely reported (1) . However, according to recent reports (1) (2) (3) , especially proven by in vitro experiments or immunohistochemical method, 3.5-17% of pituitary adenomas secrete gonadotropin. On morphological examination, so-called nonfunctioning pituitary tumors always contain secretory granules. Many of these tumors are gonadotropes (3, 4) . The preoperative evaluation whether the hypergonadotropinism is primary or secondary is not easy in an aged male. The menstrual cycle also affects the plasma gonadotropin levels in females. Furthermore, hypersecretion of follicle-stimulating hormone (FSH) does not always induce any clinical abnormalities especially in aged persons. Generally, gonadotropinoma is large whendiscovered and is resected transsphenoidally. It was reported that medical treatment for the tumor is not effective ( 1 , 5, 6) . Wereport a patient with pituitary gonadotropinoma whose plasma gonadotropin level decreased and tumor size was reduced on magnetic resonance imaging (MRI) by treatment with the dopamine agonist, bromocriptine.
Case Report
A 70-year-old male with diabetes mellitus and diabetic triopathy consulted Matsunami General Hospital complaining of headache and nausea which had persisted for four months. Brain MRIrevealed a pituitary tumor with suprasellar extension and invasion to the sphenoidal sinus. However, the optic nerve was intact. He had been treated with 10 mg/day glybenclamide and 10 IU/day insulin administration for 18 years. Diabetes mellitus had been poorly controlled and creatinine clearance was 0.78 ml/s, but recently the glycohemoglobin was 6.5-7.0%. About one year before admission, operation for bilateral cataracts was performed and photocoagulation therapy had been repeated for bilateral diabetic proliferative retinopa- 1-19.8) . Plasma oc-subunit, of which the measuring method is described elsewhere (reference range, <1.2 ng/ml) (7), was also high, 1.9-2.5 ng/ml. However, the basal plasma luteinizing hormone (LH) level was low, 0.6-1.4 IU// (age-matched reference range, 2.6-10.8). After the administration of 100 |Ug gonodotropin-releasing hormone (GnRH), plasma FSHand ocsubunit increased from 40 to 48 and 1.9 to 3.5, respectively. The increase of plasma LHwas inadequate, from 0.6 to 1.4. Administration of 500 |Ug thyrotropin-releasing hormone (TRH) paradoxically increased plasma FSH and oc-subunit levels from 40 to 62 and from 2.2 to 3.2, respectively (Fig. 1A) . However, during this stimulation, no increase was seen in the plasma LH level. Single oral administration of 2.5 mg bromocriptine slightly decreased plasma FSH and oc-subunit from 41 to 34 and from 2.5 to 1.8, respectively, but did not decrease plasma LHlevels. Subcutaneous administration of 100 |LLg octreotide acetate showedno effect on the plasma levels of FSH, a-subunit, and LH. Thyroid function was slightly decreased; plasma free triiodothyronine and free thyroxine were 2.65 pmol// (3. 80-6.68) and ll.6 nmol// (12.5-23.0), respectively.
Basal plasma TSH level was within the normal range, 2.01 [iU/l (0.34-3.5), but its response to TRHwas slightly blunted, from 2.0 to 6.6.
The increase of plasma growth hormone level after 100 |ig growth hormone-releasing hormone was also blunted, from 0.42 |i/ml to 3.95. The response of plasma prolactin to TRHand the pituitary-adrenal function evaluated by the administration of corticotropin-releasing hormone were normal. From the results of these endocrine examinations, gonadotropin-producing pituitary tumor associated with partial hypopituitarism was diagnosed. The patient refused an immediate operation of the pituitary tumor, because the tumor was not in contact with the optic nerve on MRIand the visual field was still intact, and the visual acuity was already severely impaired due to diabetic proliferative retinopathy.
Accordingly, bromocriptine was administered. As shown in Fig. 2 plasma FSH and a-subunit levels rapidly decreased to 6.0 and 0.6, respectively, when the dose of bromocriptine increased to 1 1.25 mg/day. However, plasma a-subunit level increased to a supra-normal level three monthsafter the start of the treatment, although plasma FSHlevel was still in the normal range. The dose of bromocriptine was gradually increased to 20 mg/day. Plasma a-subunit level decreased again and remained in the normal range. During the treatment, the plasma testosterone level slightly increased to 2.48 and 2.68 nmol//, which were still sub-normal levels, two and five months after the start of the treatment, respectively. The glycohemoglobin level did not change during the treatment. Five months after the start of the bromocriptine treatment, the paradoxical response of plasma FSH and a-subunit levels to the administration of TRHwas completely resolved ( size on MRIwas reduced seven months after the start of bromocriptine treatment (Fig. 3 ).
Discussion
In this patient, we did not confirm the diagnosis pathologically. However, not only was the basal plasma level of FSH high compared with the age-matched reference range, but also the plasma a-subunit level was high in the pre-treatment period. On the other hand, the basal plasma LH level was low and testosterone levels in plasma and urine were also low. The discrepancy in plasma FSHand LHlevels indicated that a secondary increase of plasma FSHlevel due to aging was unlikely. Furthermore, during the stimulation with TRH,plasma FSH and a-subunit levels paradoxically increased. These findings were consistent with previous reports on the endocrine characteristics of patients with gonadotropinoma (8) (9) (10) (11) (12) . Only a few patients whoshowedautonomoussecretion of only LHbut not FSHwere reported (1, 13) . Almost all reported patients with gonadotropinoma showed high plasma levels of FSH (1). More than half of the patients show normal or low plasma LHlevels similar to the present patient. Even in patients with high plasma LHlevels, plasma testosterone levels were low, probably because apparently supranormal plasma LHlevels were not intact LH, but, instead, were the uncombinedoc-subunits and LH-P(10).
Bromocriptine, a dopamine agonist, is effective not only in decreasing the plasma prolactin level but also in reducing the tumor size in patients with prolactinoma (14, 15) . In healthy subjects, bromocriptine decreases the plasma prolactin level, but not the gonadotropin level (16) . Sufficient effects of this drug were reported in some patients with growth hormone- ( 14, 17, 18) or corticotropin-(19) producing pituitary adenoma. In patients with thyrotropin-producing adenomabromocriptine is generally not effective (20) . Reduction of the plasma hormone level by bromocriptine treatment was reported in a few patients with gonadotropinoma (5, (21) (22) (23) . A few case reports have suggested that the occasional nonfunctioning pituitary tumor maydecrease in size in response to dopamine agonist treatment (24) (25) (26) (27) (28) . Almost all of these tumors are likely to be gonadotropinomas, because the majority of clinically nonfunctioning pituitary adenomas are gonadotropinomas (3, 4) . In a review of 84 patients with clinically nonfunctioning pituitary adenoma described in seven series between 1984 and 1989 (29), 76 of 84 tumors showedno change and one an increase in size during dopamine agonist treatment; 79 patients were treated with bromocriptine, four with mesulergine and one with pergolide. Seven of these patients showed a small decrease in tumor size (8.3%). Bromocriptine generally has an inadequate effect on reducing the size of gonadotropinomas (1, 29) . In the present patient bromocriptine clearly decreased plasma FSH and a-subunit levels, and their paradoxical increase during TRH stimulation disappeared five monthsafter the start of bromocriptine treatment. It was reported that the paradoxical response of gonadotropin to TRHstimulation seen before the treatment was resolved after the treatment of bromocriptine in a patient, as in the present patient (23) . Furthermore, the size of the tumor on MRIwas reduced. Renner et al (30) reported that the inhibition of [3H]-thymidine incorporation into gonadotropinoma cells by bromocriptine was found in gonadotropinomas in which the mRNAof the D2short (s) isoform was predominantly or equally expressed compared with the D2large (1) receptor subtype. The presence of D2S isoform in gonadotropinomas may favor the growth suppressive response to bromocriptine, although further investigation is needed. The most suitable dose and duration of bromocriptine treatmentto achieve clinical improvement and/or reduction in gonadotropinomasize are not consistent in individual cases (5, 14, 23, 24, 29) . The dose and duration reported ranged from less than 7.5 mg/day to more than 20 mg/day and from one week to longer than one year, respectively. However, it was reported that withdrawal of bromocriptine treatment led to a rapid increase in tumor size (26 (32, 33) . Octreotide was shown to inhibit the secretion of gonadotropin in patients with gonadotropinoma (6, 34) . Katznelson et al (6) reported that octreotide reduced tumor size with or without an accompanyingdecrease in serum tumor marker levels in a small percentage of patients with clinically nonfunctioning pituitary tumors and oc-subunit hypersecretion. De Bruin et al (35) reported that high-dose, 1,200 jug/day, octreotide treatment induced improvement of visual field defects in three of four patients with clinically nonfunctioning pituitary adenomaand the effect of a single injection of octreotide on the gonadotropin levels had no correlation with the improvement of the clinical efficacy. Holland et al (36) reported that, from the results of the relation of the expression of five somatostatin receptor subtypes with the effect of somatostatin and its analogs on the secretion of gonadotropin from gonadotropinomacells in culture, novel somatostatin receptor subtype specific somatostatin analogs might be of benefit in the treatment of selected patients with somatostatin receptor positive secreting tumors not responding to octapeptide somatostatin-analog.
Pure antagonists of GnRH, even in single doses, can cause profound hypogonadism in normal subjects (37) . McGrath et al (38) reported that in five men with FSH-secreting pituitary adenomas, the GnRHantagonist Nal-Glu GnRHadministered for 3-12 months decreased serum FSHconcentrations to normal or below normal. Adenomasize, however, did not change during the treatment in any of the five patients.
GnRHstimulates the secretion fo gonadotropin. However, a large amount of GnRHinduces the down-regulation of the GnRH-receptorand decreases the production and secretion of the gonadotropin (39) . It was reported that GnRHreceptor was present in gonadotropinoma cells (40) . Based on this, treatment with GnRH agonist was tried in patients with gonadotropinoma. The results of this trial, however, were not consistently successful (41, 42) .
Considering the manyreports mentioned above, the efficacy of medical treatment of gonadotropinoma is not established. It is important to reduce hormone hypersecretion and tumorsize reduction after unsuccessful surgery or in patients unable to undergo surgery.
